Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	16.27B -23.0%
Revenue (ttm)	4.60B +13.4%
Net Income	338.73M +69.2%
EPS	0.64 +62.1%
Shares Out	529.26M
PE Ratio	47.72
Forward PE	23.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	292,384
Average Volume	216,513
Open	30.75
Previous Close	30.75
Day's Range	30.75 - 31.35
52-Week Range	24.18 - 46.00
Beta	1.18
RSI	75.02
Earnings Date	Mar 19, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,041
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2025, Vimian Group AB's revenue was 425.10 million, an increase of 13.42% compared to the previous year's 374.80 million. Earnings were 31.30 million, an increase of 69.19%.

Financial numbers in EUR